Bugs & Drugs

I found that I was losing the plot about what was where! Here’s my quick guide to priority pathogens (just below) and pipeline reviews. Note in particular that a comparative Summary of the priority pathogens lists is provided. For my summary of incentives to support this pipeline, see this webpage. Corrections and amends gratefully received.

Priority Pathogen / Threat Lists

  • By my count, five priority pathogen lists have been proposed / published to date:
    1. India 2021: Newsletter is here, report is here.
    2. CDC 2019: Newsletter is here, report itself is here.
    3. WHO 2017: Newsletter is here, report itself is here.
    4. CDC 2013: Report itself is here.
    5. ESKAPE list 2008-9: This is the grandfather/mother of them all! The original papers are here:
      • (link) Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197(8):1079-81.
      • (link) Boucher HW et al. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clinical Infectious Diseases. 2009;48(1):1-12

To help you keep them organized, a comparative summary of the priority pathogen lists as a PowerPoint deck is here.

  • Please also see this newsletter for a further discussion of the priority pathogen lists as well as the idea of first- vs. best-in-class.

Pipeline Reviews (therapeutic products, unless otherwise noted)

  • Reviews by WHO
    • WHO 2022 review of preclinical and clinical vaccines (data cut-off not stated, appears to be from 2010 forward). Here are links to the report, a press release, and a newsletter about the report.
    • WHO 2022 (data cut-off 30 June 2021): My newsletter is here and the review itself is here. See also Butler et al., https://journals.asm.org/doi/10.1128/aac.01991-21) and this 17 Jan 2022 newsletter.
    • WHO 2020 (data cut-off 1 Sep 2020): My newsletter is here (and includes a video chat with Peter Beyer, one of the key drivers of the report). The review itself is here.
    • WHO 2019: My newsletter is here, commentary by WHO staff is here, the pre-clinical pipeline review is here and is supported by a data-mining interface here; the clinical pipeline review is here.
    • WHO 2017: Newsletter is here, report is here, and manuscript about the review is here.
  • Reviews by the Pew Trusts (all updated as of March 2021; see also this newsletter)
    • Go here for traditional therapeutics.
    • Go here for a visualization of pipeline changes during 2014-2020.
    • Non-traditional products are separately summarized here.
  • Independent pipeline reviews
  • Access- and Stewardship-focused reviews
    • CDDEP’s “The State of the World’s Antibiotics Report in 2021” (link) presents extensive data on global antimicrobial use and resistance, a brief pipeline review, and by-country dashboards
    • ATMF’s “2021 Access to Medicine Index” (link) summarizes progress made and work to be done on access.

A Nature Article, a PASTEUR Act Op-Ed, and a VERY Important Phone Number

Dear All, First, Nature published an excellent article entitled “The importance of antimicrobial resistance in medical mycology” by Gow et al. The first sentence of the introduction really packs a punch — “The age of antibiotics, spanning only 80 years, is now entering a period of progressive and widespread emergence of drug-resistant organisms that threaten to bring

Raising awareness of AMR: WHO report on best approaches

Dear All, In addition to forming the inaugural WHO Task Force of AMR Survivors, the WHO has also recently released a report entitled “Awareness-raising on Antimicrobial Resistance: Report of global consultation meetings.”  The report is based on discussions at two meetings held by WHO with stakeholders from across the world. Even before opening the report,

Scroll to Top